Delving into the Latest Updates on Irinotecan Hydrochloride Lioposome (Kelun) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug, Liposomal Drug

Synonyms

Irinotecan Liposome, Nanoliposomal Irinotecan, 伊立替康纳米脂质体

Target

Top I

Action

inhibitors

Mechanism

TOP1 inhibitors(DNA topoisomerase I inhibitors)

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Advanced Malignant Solid Neoplasm

Originator Organization

Sichuan Kelun Pharmaceutical Co., Ltd.

Active Organization-

Inactive Organization

Sichuan Kelun Pharmacy Institute Co., Ltd.

License Organization-

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

评估盐酸伊立替康脂质体注射液在晚期实体瘤患者中的安全性和耐受性，确定剂量限制性毒性和最大耐受剂量；评估晚期实体瘤患者静脉滴注盐酸伊立替康脂质体注射液后的药代动力学特征；比较盐酸伊立替康脂质体注射液与盐酸伊立替康注射液的药代动力学差异；观察本品的初步疗效

[Translation]

To evaluate the safety and tolerability of irinotecan hydrochloride liposome injection in patients with advanced solid tumors, determine the dose-limiting toxicity and maximum tolerated dose; to evaluate the pharmacokinetic characteristics of irinotecan hydrochloride liposome injection in patients with advanced solid tumors after intravenous infusion; to compare the pharmacokinetic differences between irinotecan hydrochloride liposome injection and irinotecan hydrochloride injection; to observe the preliminary efficacy of this product

Start Date31 May 2018

Sponsor / Collaborator

Sichuan Kelun Pharmacy Institute Co., Ltd.

100 Clinical Results associated with Irinotecan Hydrochloride Lioposome (Kelun)

Login to view more data

100 Translational Medicine associated with Irinotecan Hydrochloride Lioposome (Kelun)

Login to view more data

100 Patents (Medical) associated with Irinotecan Hydrochloride Lioposome (Kelun)

Login to view more data

100 Deals associated with Irinotecan Hydrochloride Lioposome (Kelun)

Login to view more data